Skip to content

Asset turnover at other companies

Avanos Medical logo
Avanos MedicalAVNS
0.7×+0.2×
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
0.5×0.0×
AtriCure logo
AtriCureATRC
0.9×+0.1×

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s asset turnover?
Pacira BioSciences, Inc. (PCRX) reported asset turnover of 0.5× in Q1 2026.
How has Pacira BioSciences, Inc.'s asset turnover changed year-over-year?
Pacira BioSciences, Inc.'s asset turnover increased by 18.6% year-over-year, from 0.4× to 0.5×.
What is the long-term trend for Pacira BioSciences, Inc.'s asset turnover?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s asset turnover has grown at a 4.8% compound annual growth rate (CAGR), from 0.4× to 0.5×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.